DelveInsight’s, “Dry Eye Disease Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Dry Eye Disease pipeline landscape. It covers the Dry Eye Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dry Eye Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Dry Eye Disease Treatment Landscape. Click here to read more @ Dry Eye Disease Pipeline Outlook

Key Takeaways from the Dry Eye Disease Pipeline Report

• In April 2025, Taejoon Pharmaceuticals Co., Ltd announced a drug (TJO-083) or the control drug is administered for 12 weeks, and the corneal staining of each group would be evaluated. The purpose of this clinical Study is to demonstrate that the test drug is not clinically inferior to the control drug.
• In April 2025, Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. conducted a study will evaluate the safety and efficacy of SJP-0132 in Chinese Patients with Dry Eye. Patients will be randomly assigned to receive either SJP-0132 or a placebo.
• DelveInsight’s Dry Eye Disease pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Dry Eye Disease treatment.
• The leading Dry Eye Disease Companies such as ​Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine and others.
• Promising Dry Eye Disease Pipeline Therapies such as TJO-083, Diquafosol ophthalmic sodium solution 3%, VVN001 Ophthalmic Solution, 5%, ALY688 Ophthalmic Solution, INV-102, Brimonidine, SHJ002 and others.

Stay informed about the cutting-edge advancements in Dry Eye Disease treatments. Download for updates and be a part of the revolution in Ophthalmology Care @ Dry Eye Disease Clinical Trials Assessment

Dry Eye Disease Emerging Drugs Profile

• AR-15512: Alcon

AR-15512 is an investigational eye drop currently in clinical development at Aerie as a potential treatment for the signs and symptoms of dry eye disease. The active ingredient in AR-15512 is a proprietary small-molecule selective agonist of the transient receptor potential melastatin 8 (TRPM8) cold thermoreceptor, which represents a novel therapeutic target for dry eye. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of DED.

• SI-614: Seikagaku Corporation

SI-614, an ophthalmic solution being developed by Seikagaku Corporation. CT-868 is a. SI-614 is an amphiphilic polymer produced by introducing a hydrophobic group into hyaluronic acid using Seikagaku’s own proprietary technology. Ocular instillation of SI-614 in dry eye patients is thought to stabilize the tear film by utilizing the mucoadhesive and surface tension reducing properties of SI-614 and to promote corneal epithelial wound healing by binding SI-614 to the fibronectin that occurs on corneal epithelial defects to promote epithelial cell growth. Through these actions, SI-614 is expected to restore the tear film and corneal structure to their normal state and improve symptoms associated with dry eye. Currently, the drug is in the Phase III stage of development to treat Dry Eye Disease.

• HU007: Huons

HU007 is a combination of cyclosporine, an anti-inflammatory component, and trehalose, a tear film protection component, to minimize eye surface irritation such as burning sensation by lowering the concentration of cyclosporine to less than half than that of existing treatments. In addition, it is an ophthalmic agent developed to suppress the destruction of each conjunctival epithelial cells caused by drying by combining trehalose preparations and to see the combined treatment effect for dry eyes. Currently, the drug is in the Phase III stage of development to treat Dry Eye Disease.

• A197: Aramis Biosciences

A197 is a novel topical agent that targets the immunopathogenesis of dry eye disease. It has a unique mechanism of action compared to existing dry eye treatments. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

• INV 102: Invirsa, Inc.

INV 102 is an ophthalmic eye drop being developed by Invirsa, Inc. Invirsa’s lead candidate is a naturally-occurring, small molecule that modulates the activity of p53, the central protein responsible for regulating the DNA damage response. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

• iVIEW 1001: IVIEW Therapeutics

iVIEW 1001 is a TRPM8 agonist drug being developed by iVIEW Therapeutics, Inc. to treat dry eye diseases. IVIEW 1001 is a TRPM8 agonist, which means it stimulates the transient receptor potential melastatin 8 (TRPM8) receptors in the eyelid margin. This stimulation sends a perception of coolness, reducing ocular discomfort and potentially increasing tear secretion. Currently, the drug is in the Phase I/II stage of development to treat Dry Eye Disease.

The Dry Eye Disease Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dry Eye Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.
• Dry Eye Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dry Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Eye Disease market.

Get a detailed analysis of the latest innovations in the Dry Eye Disease pipeline. Explore DelveInsight’s expert-driven report today! @ Dry Eye Disease Unmet Needs

Dry Eye Disease Companies

Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine and others.

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dry Eye Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Dry Eye Disease Treatment by visiting our website. Stay informed about how we’re transforming the future of Ophthalmology @ Dry Eye Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Dry Eye Disease Pipeline Report

• Coverage- Global
• Dry Eye Disease Companies- Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine and others.
• Dry Eye Disease Pipeline Therapies- TJO-083, Diquafosol ophthalmic sodium solution 3%, VVN001 Ophthalmic Solution, 5%, ALY688 Ophthalmic Solution, INV-102, Brimonidine, SHJ002, and others.
• Dry Eye Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dry Eye Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dry Eye Disease Pipeline on our website @ Dry Eye Disease Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Dry Eye Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dry Eye Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. AR-15512: Alcon
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. INV 102: Invirsa, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. iVIEW 1001: IVIEW Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dry Eye Disease Key Companies
21. Dry Eye Disease Key Products
22. Dry Eye Disease- Unmet Needs
23. Dry Eye Disease- Market Drivers and Barriers
24. Dry Eye Disease- Future Perspectives and Conclusion
25. Dry Eye Disease Analyst Views
26. Dry Eye Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight